Bone Solutions Inc. has successfully completed 250 cases with OsteoCrete® Magnesium-Based Bone Void Filler.

Tuesday, October 2, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

DALLAS, Oct. 2, 2018 /PRNewswire/ -- Bone Solutions Inc. (BSI), an ortho-biologics technology company announces the first

250 cases of implanted OsteoCrete®.  OsteoCrete® is a Magnesium-based bone void filler is designed to assist with bone repair and generation, and it's the first in the U.S. to incorporate magnesium, a critical property for bone
health and development.

"In our initial launch phase, we have successfully implanted over 2200cc's of OsteoCrete® bone void filler. OsteoCrete® provides a combination of compressive strength, non-expanding features, and characteristics for optimal binding qualities. OsteoCrete® is 100% resorbable which makes it ideal for surgeons while providing enhanced patient outcomes. Many modern devices used for bone repair or replacement are calcium-based and do not exhibit the same quality or features as OsteoCrete®.

BSI will be immediately expand our clinical and commercial footprint, establishing various distribution partners throughout US.  This will allow the company to build a stronger presence in the marketplace for bone graft substitutes." stated BSI president and CEO, Drew Diaz.

About Bone Solutions Inc.

Bone Solutions Inc. ('BSI') (www.bonesolutionsinc.com) is an orthobiologics company with a vision to provide orthopedic surgeons a means to improve clinical outcomes in a number of complex procedures while lowering costs. The company is revolutionizing a new solution for orthopedic surgeons for human uses with their FDA-cleared magnesium-based platform bone void filler.

Media Contact:

Bone Solutions Inc.:Drew DiazPresident/CEO817-809-8850diaz@bonesolutions.net

 

Cision View original content:http://www.prnewswire.com/news-releases/bone-solutions-inc-has-successfully-completed-250-cases-with-osteocrete-magnesium-based-bone-void-filler-300720483.html

SOURCE Bone Solutions Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store